Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of JR-401 (somatropin) weekly dose levels in pediatric growth hormone deficiency
jRCT2051250213Phase 3Recruiting
- Sponsor
- JCR Pharmaceuticals
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by JCR Pharmaceuticals. Primary endpoint: Change in height SDS for chronological age at Week 52. Started Mar 2026; status: recruiting.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on jRCT2051250213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250213.